September 27th 2023
Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.
October 8th 2021
Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.